undamentalytics Newsletter
Sign in

10x Genomics, Inc. (TXG) stock

Add to watchlist

Add holding +

NASDAQ: TXG Nasdaq Life Sciences Tools & Services Next results ~November 5, 2026

C Fundamentals grade

10x Genomics, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$16

Forward price-to-sales vs peers

Base case. Range ~$13–$33. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

10x Genomics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 6 selling0 purchases and 50 sales by directors and officers, last 12 monthsInsider trades
  • Funds194 adding, 170 cuttingOf 58 active managers that changed their stake, 29 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter 10x Genomics files

Where 10x Genomics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $617m, down 4.3% on a year earlier, against growth of 2.3% a quarter earlier. That puts it 30 of 31 for growth among the life sciences tools & services companies we cover. Free-cash-flow margin rose to 19.7% from 8.8% a year earlier. The diluted share count is up 4.2% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 2 financial-health checks. Our revenue-to-maturity cash-flow model value is $9.86 a share, against a share price of $82.82.

Source: 10-Q filed August 7, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

10x Genomics, Inc.'s trailing-twelve-month revenue fell 4.3% year on year, with a free-cash-flow margin of 19.7%. Where it stands out: days sales outstanding of 28 days ranks 5 of 48 life sciences tools & services companies we cover. Where it lags: revenue growth of -4.3% ranks 47 of 54 life sciences tools & services companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 113.5% while net income grew 11.2%: a 102pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.5bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Revenue shrinking. Revenue fell 4.3% over the last 12 months.
  • Growth slowing. The growth rate is 6.5 points lower than a quarter earlier.
  • Loss-making. Operating margin is -14.3%: costs exceed revenue.
  • Heavy stock-based pay. Stock pay equals 16.0% of revenue, against a median of 4.4% for life sciences tools & services companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 4.2% in a year.
  • High sales multiple. The shares trade at 13 times revenue while operating margins remain thin.

Latest results: FY2026 Q2

Filed August 7, 2026
Earnings per share
$0.03 against an average estimate of -$0.02: beat by 258.4%
Revenue
$151m, down 12.6% on a year earlier
Share reaction
+9.6% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.02

10x Genomics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-12.1%
  • 1 week-15.5%
  • 1 month-34.1%
  • This year+277.9%
  • 1 year+351.8%
  • 5 years-62.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$617M
Operating margin
-14.3%
Net margin
-12.2%
EPS (TTM, diluted)
$-0.59

Growth

Revenue growth
−4.3%
Change in growth rate
−6.5 pts
Share count change
+4.2%

Cash

Free cash flow (TTM)
$121M
FCF margin
19.7%
Stock pay % of revenue
16.0%

Earnings

Last results
August 6, 2026

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Product
  2. Leadership
  3. Insider trade
  4. Insider trade
  5. Insider trade
  6. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

10x Genomics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value 10x Genomics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.4%: the 10-year Treasury yield (4.9%) plus a beta of 1.21 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$9.6 ~$7.5–$11 Left out: out of range vs price (0.16x)
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.8 ~$1.4–$2.4 Left out: out of range vs price (0.03x)
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$16 ~$13–$33 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$9.9 ~$9.9–$11 Left out: out of range vs price (0.16x)
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$16 ~$13–$33 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare 10x Genomics, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2019202020212022202320242025Now
Share price$76.25$141.60$148.96$36.44$55.96$14.36$16.31$61.63
Market value$3.0bn$14.3bn$16.4bn$4.1bn$6.6bn$1.7bn$2.0bn$7.9bn
+ Net debt (− = net cash)−$424m−$664m−$587m−$220m−$359m−$344m−$474m−$503m
Enterprise value$2.6bn$13.7bn$15.8bn$3.9bn$6.2bn$1.4bn$1.6bn$7.4bn
Multiples
Price / sales 12.1x47.9x33.5x8.0x10.6x2.8x3.2x12.7x
Price / earnings ————————
Price / free cash flow ——————15.6x64.7x
EV / EBITDA ————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

33 /100

Weak moat

How hard 10x Genomics's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 9 / 20

    Cash operating profit has been a median 7.7% of total assets over 7 years.

  • Pricing power 16 / 20

    Gross margin has been a median 74.3%, moving by 6.2 percentage points (standard deviation) across 8 years.

  • Durability 10 / 20

    Operating margin has been a median -30.9%; its worst year was -122.1%.

  • Cash conversion 3 / 20

    Free cash flow was positive in 2 of 7 years, at a median -18.3% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 19.4% over five years; stock-based pay has been a median 18.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (38 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $148m and EPS of −$0.02 (range −$0.04 to $0.00) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.04 −70% $621m −4%
Next $0.08 +109% $683m +10%

Next year's EPS estimate has moved −62.9% in 90 days, across 3 analysts.

How the EPS forecast has moved

In the last 30 days, 1 analyst raised 10x Genomics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast 10x Genomics, Inc., last 90 days
$0.00 $0.10 $0.20 $0.30 60 days ago 30 days ago 7 days ago Now Current fiscal year, 60 days ago: $0.10 Current fiscal year, 30 days ago: $0.10 Current fiscal year, 7 days ago: $0.04 Current fiscal year, Now: $0.04 $0.04 Next fiscal year, 90 days ago: $0.21 Next fiscal year, 60 days ago: $0.20 Next fiscal year, 30 days ago: $0.20 Next fiscal year, 7 days ago: $0.08 Next fiscal year, Now: $0.08 $0.08

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
60 days ago $0.10$0.21
30 days ago $0.10$0.20
7 days ago $0.04$0.20
Now $0.04$0.08

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.02 $0.03 +258.4%
Mar 2026 −$0.06 $0.07 +219.2%
Dec 2025 −$0.04 $0.07 +276.2%
Sept 2025 −$0.07 −$0.02 +67.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

18 analysts, Oct 2026
Buy633%
Hold1267%
Sell00%

Monthly trend

  1. Oct 202651218
  2. Sep 202661219
  3. Aug 202651016
  4. Jul 202651016

Counts of recommendations published by analysts covering 10x Genomics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
14.3%
of tradable shares
Days to cover
3.09
at average volume
Short interest, 1 month
−24%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.4%
of shares
Employees
1,178
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months +351.8%

$13.64 on October 31, 2025 to $61.63

ThenNowEffect
Revenue (last 12 months) $644m $617m −4.3%
P/S multiple 2.6x 12.7x +392.0%
Share count 122m 128m −4.1%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +55.2%

$39.72 on November 3, 2023 to $61.63

ThenNowEffect
Revenue (last 12 months) $568m $617m +8.5%
P/S multiple 8.1x 12.7x +58.1%
Share count 115m 128m −9.6%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
TXG+5%−76%+54%−74%+14%+278%
Industry peers (median)+4%−51%−3%−13%−7%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
TXG50%17%67%25%58%73%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
TXG−34%−84%−46%−76%−56%−37%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since September 12, 2019: 97% from April 26, 2021 to April 8, 2025. Getting back needed a 2734% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$13.00 – $97.74
From 52-week high
−36.9%
vs 50-day average
−16.8%
vs 200-day average
+51.1%
Volatility (1 year)
77%
Beta vs S&P 500
2.41

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±6.9%
After a week
8 up, 4 down
typical move ±11.3%
After a month
6 up, 6 down
typical move ±18.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +9.6% +0.5% +22.5% +32.0%
May 7, 2026 −5.0% +0.5% −5.4% +28.3%
February 12, 2026 −5.4% −1.5% −1.4% −12.8%
January 12, 2026 +0.3% 0.0% +7.8% −6.4%
November 6, 2025 +13.0% −1.0% +21.2% +29.5%
August 7, 2025 −2.9% +0.7% +4.6% +10.0%
May 8, 2025 +5.5% +0.6% +10.7% +21.4%
February 12, 2025 +1.0% +0.7% −2.2% −12.5%
January 13, 2025 −0.9% +0.3% +3.7% −23.0%
October 29, 2024 +4.0% −0.1% +9.3% −2.4%
October 9, 2024 −22.1% +0.5% −21.7% −19.6%
August 8, 2024 +12.7% +2.8% +24.9% +20.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

10x Genomics, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) 10x Genomics, Inc.
$580M $600M $620M $640M $660M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $591M Revenue (TTM), FY23 Q4: $618.7M Revenue (TTM), FY24 Q1: $625.4M Revenue (TTM), FY24 Q2: $631.7M Revenue (TTM), FY24 Q3: $629.7M Revenue (TTM), FY24 Q4: $610.8M Revenue (TTM), FY25 Q1: $624.7M Revenue (TTM), FY25 Q2: $644.5M Revenue (TTM), FY25 Q3: $641.8M Revenue (TTM), FY25 Q4: $642.8M Revenue (TTM), FY26 Q1: $638.8M Revenue (TTM), FY26 Q2: $616.9M $616.9M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $591M
FY23 Q4 $618.7M
FY24 Q1 $625.4M
FY24 Q2 $631.7M
FY24 Q3 $629.7M
FY24 Q4 $610.8M
FY25 Q1 $624.7M
FY25 Q2 $644.5M
FY25 Q3 $641.8M
FY25 Q4 $642.8M
FY26 Q1 $638.8M
FY26 Q2 $616.9M
Revenue growth, TTM YoY 10x Genomics, Inc.
-10% 0% 10% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 17.3% Revenue growth, TTM YoY, FY23 Q4: 19.8% Revenue growth, TTM YoY, FY24 Q1: 16.6% Revenue growth, TTM YoY, FY24 Q2: 11.1% Revenue growth, TTM YoY, FY24 Q3: 6.6% Revenue growth, TTM YoY, FY24 Q4: -1.3% Revenue growth, TTM YoY, FY25 Q1: -0.1% Revenue growth, TTM YoY, FY25 Q2: 2.0% Revenue growth, TTM YoY, FY25 Q3: 1.9% Revenue growth, TTM YoY, FY25 Q4: 5.2% Revenue growth, TTM YoY, FY26 Q1: 2.3% Revenue growth, TTM YoY, FY26 Q2: -4.3% -4.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 17.3%
FY23 Q4 19.8%
FY24 Q1 16.6%
FY24 Q2 11.1%
FY24 Q3 6.6%
FY24 Q4 -1.3%
FY25 Q1 -0.1%
FY25 Q2 2.0%
FY25 Q3 1.9%
FY25 Q4 5.2%
FY26 Q1 2.3%
FY26 Q2 -4.3%
Operating margin (TTM) 10x Genomics, Inc.
-60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -39.5% Operating margin (TTM), FY23 Q4: -42.9% Operating margin (TTM), FY24 Q1: -43.9% Operating margin (TTM), FY24 Q2: -40.1% Operating margin (TTM), FY24 Q3: -31.7% Operating margin (TTM), FY24 Q4: -31.9% Operating margin (TTM), FY25 Q1: -27.6% Operating margin (TTM), FY25 Q2: -15.6% Operating margin (TTM), FY25 Q3: -14.2% Operating margin (TTM), FY25 Q4: -9.5% Operating margin (TTM), FY26 Q1: -6.1% Operating margin (TTM), FY26 Q2: -14.3% -14.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -39.5%
FY23 Q4 -42.9%
FY24 Q1 -43.9%
FY24 Q2 -40.1%
FY24 Q3 -31.7%
FY24 Q4 -31.9%
FY25 Q1 -27.6%
FY25 Q2 -15.6%
FY25 Q3 -14.2%
FY25 Q4 -9.5%
FY26 Q1 -6.1%
FY26 Q2 -14.3%
FCF margin (TTM) 10x Genomics, Inc.
-20% -10% 0% 10% 20% 30% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -19.0% FCF margin (TTM), FY23 Q4: -10.3% FCF margin (TTM), FY24 Q1: -11.8% FCF margin (TTM), FY24 Q2: -5.1% FCF margin (TTM), FY24 Q3: 4.1% FCF margin (TTM), FY24 Q4: -0.9% FCF margin (TTM), FY25 Q1: 7.3% FCF margin (TTM), FY25 Q2: 8.8% FCF margin (TTM), FY25 Q3: 12.7% FCF margin (TTM), FY25 Q4: 20.2% FCF margin (TTM), FY26 Q1: 19.1% FCF margin (TTM), FY26 Q2: 19.7% 19.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -19.0%
FY23 Q4 -10.3%
FY24 Q1 -11.8%
FY24 Q2 -5.1%
FY24 Q3 4.1%
FY24 Q4 -0.9%
FY25 Q1 7.3%
FY25 Q2 8.8%
FY25 Q3 12.7%
FY25 Q4 20.2%
FY26 Q1 19.1%
FY26 Q2 19.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 71 146 246 299 490 516 619 611 643 617
Gross profit 61 118 185 240 416 396 409 414 444 432
EBITDA −14 −107 −24 −520 −31 −143 −230 −159 −25 −48
Operating income −18 −111 −31 −534 −52 −168 −265 −195 −61 −88
Net income −19 −112 −31 −543 −58 −166 −255 −183 −44 −75
Diluted EPS −$0.54 −$2.80 −$0.80 −$5.37 −$0.53 −$1.46 −$2.18 −$1.52 −$0.35 −$0.59
Growth (year on year)
Revenue — +105.8% +68.1% +21.5% +64.1% +5.3% +19.8% −1.3% +5.2% −4.3%
Margins
Gross margin 85.1% 80.4% 75.2% 80.4% 84.9% 76.7% 66.2% 67.9% 69.1% 70.0%
EBITDA margin −19.8% −73.0% −9.6% −174.0% −6.3% −27.6% −37.1% −26.0% −3.9% −7.8%
Operating margin −25.8% −75.7% −12.4% −178.7% −10.7% −32.5% −42.9% −31.9% −9.5% −14.3%
Net margin −26.4% −76.9% −12.7% −181.6% −11.9% −32.1% −41.2% −29.9% −6.8% −12.2%
Free-cash-flow margin −20.3% −56.5% −3.3% −85.2% −25.0% −32.0% −10.3% −0.9% 20.2% 19.7%
Cash flow
Cash from operations −11 −76 35 −218 −21 −34 −15 7 136 127
Capital spending 4 6 43 37 101 132 49 12 6 6
Free cash flow −14 −83 −8 −255 −123 −165 −64 −6 130 121
Stock-based pay 2 3 13 49 96 137 167 141 109 99
Free cash flow after stock pay −16 −85 −21 −303 −219 −302 −231 −146 21 23
Balance sheet
Cash 48 65 424 664 587 220 359 344 474 503
Total debt 0 30 — 0 0 0 0 0 0 0
Net debt (negative = net cash) −48 −35 −424 −664 −587 −220 −359 −344 −474 −503
Diluted shares 35m 40m 39m 101m 110m 114m 117m 120m 125m 128m
Returned to shareholders
Buybacks 0 — — — — — — — — —
Total returned 0 — — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $1.0bn
Short-term assets $675mLonger-term assets $355m
What it owes, and who funded it · $1.0bn
Short-term liabilities $119mLonger-term liabilities $86mShareholders' equity $826m
  • Short-term assets cover short-term liabilities $675m of assets due within a year against $119m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $675m short-term assets against $86m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From 10x Genomics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+4.2%
year over year
R&D spending
36.8%
of revenue
Sales & admin spending
48.1%
of revenue
Days sales outstanding
28 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated TXG AZTA VCYT NEO RGEN TWST Median
Revenue, last 12 months $617m $614m $562m $788m $806m $432m $229m
Revenue growth, last 12 months −4.3% 4.9% 17.3% 11.1% 13.8% 19.2% 6.9%
Revenue growth, 3-year average 2.8% −0.9% 19.6% 11.1% 7.3% 22.4% 2.9%
Revenue growth, latest quarter −12.6% 12.0% 15.5% 11.4% 10.9% 23.2% 8.5%
Gross margin 70.0% 44.0% 71.7% 44.8% 53.5% 52.0% 51.9%
Operating margin −14.3% −28.6% 18.8% −6.3% 2.3% −33.6% −14.3%
Operating margin, 3-year average −23.3% −15.0% 1.6% −12.5% 1.4% −50.8% −22.4%
Net margin −12.2% −20.0% 20.4% −4.1% −1.5% −31.7% −16.1%
Cash from operations / revenue 20.6% 6.2% 31.7% 0.5% 16.1% −12.3% 1.3%
Free-cash-flow margin 19.7% 1.6% 29.5% −3.6% 13.2% −21.6% −2.2%
Free-cash-flow margin, 3-year average 7.8% 5.0% 19.0% −3.1% 16.6% −22.0% 0.6%
Stock pay / revenue 16.0% 3.1% 8.6% 4.4% 4.2% 15.4% 4.4%
Change in share count 4.2% −1.1% 2.5% 1.2% 0.3% 2.4% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth -4.3% 6.9% 47 of 54
Change in growth rate Growth -6.5pp +0.4pp 47 of 54
Gross margin Profitability 70.0% 52.0% 6 of 45
Operating margin Profitability -14.3% -14.3% 26 of 52
Net margin Profitability -12.2% -12.2% 27 of 54
Free-cash-flow margin Cash generation 19.7% -1.3% 9 of 54
Stock pay as % of revenue Cash generation 16.0% 4.4% 45 of 53
Change in share count Balance sheet 4.2% 1.0% 34 of 46
Days sales outstanding Balance sheet 28 days 62 days 5 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Product and Service Revenue $597M ▼ 2.3%
Consumables $507M ▲ 2.8%
Single Cell Consumables $363M ▼ 2.4%
Spatial Consumables $144M ▲ 18.9%
Instruments $56.8M ▼ 38.8%
Licensing and Royalty Revenue $46.1M ▲ 14272.3%
Spatial Instruments $34.1M ▼ 40.7%
Services $32.7M ▲ 34.6%
Single Cell Instruments $22.7M ▼ 35.6%

These categories overlap or exclude eliminations, so shares aren't shown.

Geography
Region Revenue Share YoY
Americas $359M 55.8% ▲ 3.2%
United States $347M 96.6% ▲ 3.6%
Americas Excluding United States $12.3M 3.4% ▼ 8.8%
EMEA $162M 25.2% ▲ 1.2%
Asia Pacific $122M 19.0% ▲ 18.5%
China $70.3M 57.4% ▲ 22.6%
Asia Pacific Excluding China $52.1M 42.6% ▲ 13.3%

From 10x Genomics, Inc.'s 10-K filed February 13, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$4.9B
Institutions reporting
389
Shares held vs prior quarter
▲ 2.7%
Positions opened / closed
95 / 32

Top buyers and sellers, Q2 2026: 194 institutions bought and 170 sold ; the biggest buyer was Price T Rowe Associates Inc (+4.4M shares) and the biggest seller Millennium Management LLC (−2.0M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $676M 17.6M 13.7% ▼ 0.6%
Blackrock, Inc. $414M 10.8M 8.4% ▲ 7.2%
ARK Investment Management LLC $384M 10.0M 7.8% ▼ 14.6%
Vanguard Portfolio Management LLC $268M 7.0M 5.4% ▲ 1.0%
Quantinno Capital Management LP $210M 5.5M 4.3% ▲ 1.1%
Vanguard Capital Management LLC $195M 5.1M 4.0% ▼ 3.5%
Price T Rowe Associates Inc $174M 4.5M 3.5% ▲ 2681.0%
Sumitomo Mitsui Trust Group, Inc. $161M 4.2M 3.3% ▼ 17.9%
Amova Asset Management Americas, Inc. $161M 4.2M 3.3% ▼ 17.9%
Morgan Stanley $129M 3.4M 2.6% ▲ 26.2%
Goldman Sachs Group Inc $121M 3.1M 2.5% ▼ 20.7%
Geode Capital Management, LLC $118M 3.1M 2.4% ▲ 6.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not 10x Genomics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $16.9M 50 trades by 6 insiders · 57% under pre-set plans
Net ▼ $16.9M net selling
Insider Date Trade Shares Price Value
Saxonov Serge Chief Executive Officer September 22, 2026 Sell pre-set plan 2,800 $82.37 $230,636
Saxonov Serge Chief Executive Officer September 22, 2026 Sell pre-set plan 2,000 $79.62 $159,240
Saxonov Serge Chief Executive Officer September 22, 2026 Sell pre-set plan 9,300 $80.90 $752,370
Saxonov Serge Chief Executive Officer September 22, 2026 Sell pre-set plan 9,900 $81.83 $810,117
Saxonov Serge Chief Executive Officer September 22, 2026 Sell pre-set plan 1,000 $78.23 $78,230
Suliman Shehnaaz Director September 22, 2026 Sell pre-set plan 1,222 $82.28 $100,546
Suliman Shehnaaz Director September 22, 2026 Sell pre-set plan 614 $79.51 $48,819
Suliman Shehnaaz Director September 22, 2026 Sell pre-set plan 292 $78.20 $22,834
Suliman Shehnaaz Director September 22, 2026 Sell pre-set plan 2,270 $81.67 $185,391
Suliman Shehnaaz Director September 22, 2026 Sell pre-set plan 1,325 $80.82 $107,086
Taich Adam Chief Financial Officer September 9, 2026 Sell pre-set plan 31,428 $64.31 $2M
Taich Adam Chief Financial Officer September 9, 2026 Sell pre-set plan 13,754 $65.26 $897,586

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 29, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • February 12, 2026
  • January 12, 2026
  • November 6, 2025
  • August 7, 2025

Recent SEC filings

Data status

When each part of this page on 10x Genomics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

10x Genomics, Inc. in brief

What does 10x Genomics, Inc. do?
10x Genomics, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is 10x Genomics, Inc.'s stock ticker?
10x Genomics, Inc. trades under the ticker TXG on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is 10x Genomics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, 10x Genomics, Inc. reported revenue of $617M, 4.3% lower than a year earlier, according to its SEC filings.
What is 10x Genomics, Inc.'s free cash flow?
10x Genomics, Inc.'s free-cash-flow margin is 19.7% of revenue over the trailing twelve months, ranking 9 of the 54 life sciences tools & services companies we cover.
Who are 10x Genomics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Blackrock, Inc. and ARK Investment Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is 10x Genomics, Inc.'s market cap?
On November 2, 2026, 10x Genomics, Inc.'s market capitalisation was about $7.9B and net debt of -$503M. Market figures come from third-party market data and may be delayed.
Who are 10x Genomics, Inc.'s competitors?
In our Life Sciences Tools & Services peer group, the companies closest to 10x Genomics, Inc. are Azenta, Inc., Veracyte, Inc., Neogenomics Inc, Repligen Corp and Twist Bioscience Corp. The side-by-side comparison below sets their revenue, margins and growth against 10x Genomics, Inc.'s.
Are insiders buying or selling 10x Genomics, Inc. stock?
Over the last 12 months, 10x Genomics, Inc.'s directors and officers reported 0 open-market purchases and 50 sales on Form 4. The insider trading page charts every trade.
When is 10x Genomics, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — 10x Genomics, Inc. announces its own schedule.